Novartis' big PD-1 bet turns sour; $350M resurrection story; Contraceptive for men heads to clinic; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The Drug Information Association’s annual meeting may not have been on everyone’s radar, but the conversations there could be just as relevant for the industry as a whole. And if you missed Endpoints senior editor Zach Brennan’s series of fireside chats and panels looking at the FDA’s next five years, we now have the full videos and transcripts available. Check them out below.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.